Results 101 to 110 of about 10,059 (251)

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America [PDF]

, 2017
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America.
Andes, David, Benjamin, Daniel K., Calandra, Thierry F., Edwards, John E., Filler, Scott G., Fisher, John F., Kauffman, Carol A., Kullberg, Bart-Jan, Pappas, Peter G., Reboli, Annette C., Rex, John H., Sobe, Jack D., Walsh, Thomas J., Zeichner, Luis Ostrosky   +13 more
core  

Clinical Characteristics and Genomic Analysis of a Trichophyton indotineae Strain Resistant to Terbinafine and Fluconazole Isolated in Italy

Mycoses, Volume 68, Issue 8, August 2025.
ABSTRACT Background Antifungal resistance is an expanding and increasingly significant issue representing a global threat for public health. In the last few years, different cases of dermatophytosis infections due to terbinafine‐resistant Trichophyton mentagrophytes have been reported worldwide. In particular, T.
Paolo Gaibani, Paolo Cattaneo, Michela Deiana, Caterina Signoretto, Annarita Sorrentino, Denise Lavezzari, Gloria Burlacchini, Elena Locatelli, Simone Malagò, Pierantonio Orza, Chiara Piubelli, Luca Rossi, Tamara Ursini, Francesca Perandin   +13 more
wiley   +1 more source

Anidulafungin dosing during CRRT: do not underestimate adsorption! [PDF]

Critical Care, 2014
Two recent papers in Critical Care discuss the use of echinocandins in general [1], and anidulafungin in particular [2], during continuous renal replacement therapy (CRRT). Being highly protein bound and predominantly nonrenally eliminated drugs, echinocandins are barely removed by convection and thus require no dose adjustment during CRRT. Based on
Honoré, Patrick M, Jacobs, Rita, De Waele, Elisabeth, Spapen, Herbert D   +3 more
openaire   +4 more sources

Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis

International Journal of Infectious Diseases, 2019
Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that ...
D.V. Pérez Civantos, M. Robles Marcos, J.R. Azanza Perea, C. Pazos Pacheco, F. García-Montoto Pérez, V. Jerez Gómez-Coronado   +5 more
doaj   +1 more source

Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases

BMC Medicine, 2022
Background The severe fever with thrombocytopenia syndrome disease (SFTS), caused by the novel tick-borne SFTS virus (SFTSV), was listed among the top 10 priority infectious disease by World Health Organization due to the high fatality rate of 5–30% and ...
Shu Shen, Yaxian Zhang, Zhiyun Yin, Qiong Zhu, Jingyuan Zhang, Tiantian Wang, Yaohui Fang, Xiaoli Wu, Yuan Bai, Shiyu Dai, Xijia Liu, Jiayin Jin, Shuang Tang, Jia Liu, Manli Wang, Yu Guo, Fei Deng   +16 more
doaj   +1 more source

An on-line solid phase extraction procedure for the routine quantification of caspofungin by liquid chromatography-tandem mass spectrometry [PDF]

, 2012
Background: Extensive sets of data are required to investigate the potential use of a therapeutic drug monitoring with individualization of dosage of the antimycotic compound caspofungin.
Kirchhoff, Fabian, Maier, Barbara, Ostermann, Helmut, Rieger, Christina, Spoehrer, Ute, Vogeser, Michael   +5 more
core   +1 more source

Susceptibility of the Candida haemulonii Complex to Echinocandins: Focus on Both Planktonic and Biofilm Life Styles and a Literature Review

Journal of Fungi, 2020
Candida haemulonii complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) is well-known for its resistance profile to different available antifungal drugs.
Lívia S. Ramos, Laura N. Silva, Marta H. Branquinha, André L. S. Santos   +3 more
doaj   +1 more source

‘Case of the Month’ from Herlev and Gentofte Hospital, Denmark: candidaemia and fungus ball in a patient with diabetes on sodium‐glucose co‐transporter 2 inhibitor

BJU International, Volume 136, Issue 3, Page 408-411, September 2025.
Anne Sofie Frøkiær Mathiasen, Maria Feldborg Bruun Andersen, Valeria Antsupova, Mikkel Fode   +3 more
wiley   +1 more source

ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

Mycoses, Volume 68, Issue 7, July 2025.
ABSTRACT Introduction Invasive fungal infections (IFI) are a major clinical challenge, particularly in immunocompromised patients, and are associated with high morbidity and mortality. With the increasing prevalence of immunosuppressive conditions and ageing populations, the incidence of IFI is rising globally.
Robina Aerts, Lize Cuypers, Eelco F. J. Meijer, Michel Kohnen, Jacques F. Meis, Oliver A. Cornely, Katrien Lagrou, Jon Salmanton‐García, Alex Wagemakers, Stefan Vestjens, Peter Verbeeck, Geert Vanheule, Marc Vandevelde, Jens van Van Praet, Bruno van Van Herendael, Jaap van Doesum, Karin van Van Dijk, Alieke van der Van der Hoeven, Wendy W. J. van de Van de Sande, Marijke Reynders, Ann Packeu, Yarah Overmeire, Claudy Oliveira‐dos‐Santos, Eric Nulens, Alexandre Mzabi, Astrid Muyldermans, Isabel Montesinos, Willem Melchers, Johan Maertens, Karel Maelegheer, Sybren Lekkerkerk, Nathalie Layios, Eva Kolwijck, Stijn Jonckheere, Louis Ide, Marie‐Pierre Hayette, Ferry Hagen, Pieter‐Jan Haas, Truus Goegebuer, Peggy Godschalk, Anne‐Isabelle de Moreau, Emmanuel de Laere, Julien de Greef, Deborah de Geyter, Peter Croughs, Philippe Clevenbergh, Jolien Claessens, Ga‐Lai Chong, Reinoud Cartuyvels, Jochem Buil, Roger Bruggemann, Jerina Boelens, An Boel, Robbert Bentvelsen   +53 more
wiley   +1 more source

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome

BMC Infectious Diseases, 2011
Background Candida albicans is the most common cause of candidemia and other forms of invasive candidiasis. Systemic infections due to C. albicans exhibit good susceptibility to fluconazole and echinocandins.
Reisman Arlene L, Schlamm Haran T, Kett Daniel H, Pappas Peter G, Rotstein Coleman, Shorr Andrew F, Reboli Annette C, Biswas Pinaki, Walsh Thomas J   +8 more
doaj   +1 more source